Breadcrumb

Breadcrumbs

Press Releases

Press Releases

News, Events, Updates, Breakthroughs

Journalists may direct questions to mediainquiries@dsi.com. Or click here for direct contact information for Daiichi Sankyo U.S. Public Affairs team

Press announcements are archived by release date, searchable by topic:

From To
Date Title
2019.03.28
Daiichi Sankyo Confirms Plans to Accelerate BLA Submission to U.S. FDA for [Fam-] Trastuzumab Derux ...
PDF (192 KB)
2019.02.22
Daiichi Sankyo Shifts Several Top Leaders to New Roles for Company’s Launch into its Next Growth Ph ...
PDF (179 KB)
2019.02.05
FDA Grants Priority Review for Daiichi Sankyo’s New Drug Application for CSF1R Inhibitor Pexidartin ...
PDF (190 KB)
2019.01.29
Carrie Ann Inaba Partners with Daiichi Sankyo, Inc. to Encourage Americans to “Get Iron Informed”
PDF (474 KB)
2019.01.14
Daiichi Sankyo Initiates Pivotal Phase 3 Trial of [Fam-] Trastuzumab Deruxtecan (DS-8201) in HER2 L ...
PDF (265 KB)
2018.12.19
Daiichi Sankyo Initiates First Novel-Novel Combination Study of Two Investigational Agents within i ...
PDF (140 KB)
2018.12.17
Daiichi Sankyo Out-Licenses ROS1/NTRK Inhibitor DS-6051 to AnHeart Therapeutics
PDF (244 KB)
2018.12.10
Daiichi Sankyo and Sarah Cannon Research Institute Launch Strategic Collaboration to Develop Novel ...
PDF (313 KB)
2018.12.08
Daiichi Sankyo Presents Updated Phase 1 Results of [Fam-] Trastuzumab Deruxtecan (DS-8201) in Patie ...
PDF (275 KB)
2018.12.05
Daiichi Sankyo Presents Updated Phase 1 Data for U3-1402 in Patients with HER3-Expressing Metastati ...
PDF (439 KB)
Showing 11 - 20 of 47 results.

Press Release More Stories

More Stories

Who We Are

As the U.S. subsidiary of a global pharmaceutical innovator, Daiichi Sankyo, Inc. draws on a rich heritage of innovation, integrity and accountability..

read more ...